Press Release Details

Quest Diagnostics Granted CDC Contract to Support COVID-19 Infection and Vaccination Seroprevalence Research

March 23, 2022

Quest to employ its comprehensive menu of COVID-19 antibody test and data analytics services to support population health research across 45 states and Puerto Rico

SECAUCUS, N.J., March 23, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has been granted a contract by the Centers for Disease Control and Prevention (CDC) to perform testing and provide laboratory data analysis to help identify patterns in SARS-COV-2 seroprevalence on a multistate basis. The goal is to aid the CDC in assessing the proportion of the population that has been infected by or vaccinated against SARS-CoV-2, the virus that causes COVID-19.

Quest was awarded the contract following a competitive bid. The total contract value with all options is valued at up to approximately $19.5 million.

The new agreement extends and broadens the scope of the company's contributions to the CDC's seroprevalence research, which includes participating in the SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology and Surveillance (SPHERES) consortium. Quest will utilize serum specimen remnants from clinical testing for a range of non-COVID-19 conditions to identify immune response to SARS-CoV-2 using its comprehensive menu of COVID-19 serological tests. The company's serological tests are authorized by the U.S. Food and Drug Administration for emergency use and aid in identifying antibodies produced in response to recent or prior infection and/or vaccination. Quest will provide the data analysis to the CDC in a HIPAA-compliant manner to support public health analysis and reporting. 

"From the earliest days of the pandemic, public-private collaboration has been essential to effective response to the COVID-19 threat," said Catherine T. Doherty, Senior Vice President, Group Executive – Clinical Franchise Solutions & Marketing, Quest Diagnostics. "Quest Diagnostics has a powerful combination of quality COVID-19 serological testing, national reach and robust data analytics to deliver insights to inform public health strategies. We are proud to bring these assets to the CDC's efforts to track the nation's vulnerability to COVID-19."

Quest and the CDC have collaborated on several initiatives to improve population health analysis based on insights from Quest's national testing data. In January 2021, the company formed an agreement to provide SARS-CoV-2 variant sequencing to help identify and track new variants. Quest and CDC have also collaborated on research to assess the pandemic's impact on nonprescribed fentanyl use in individuals with opioid use disorder and hepatitis C screening and diagnostic trends.

About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors, and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. Learn more at or follow us on social media: LinkedIn, Twitter, Facebook and Instagram. For information on our COVID-19 testing, visit:

Cision View original content to download multimedia:

SOURCE Quest Diagnostics